Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers – Where are we now?

Christopher Aboo, Tue Wenzel Krastrup, Helene Broch Tenstad, Jie Ren, Søren Andreas Just, Morten Ladekarl, Allan Stensballe*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Introduction: Immune-checkpoint inhibitors (ICI) works by blocking inhibitory signals of T cells. This produces an effective anti-tumor response but can also cause immune-related adverse events (irAEs). Most irAEs are transient, but ICI-induced inflammatory arthritis (ICI-IIA) might become chronic and affect the quality-of-life, or even necessitate treatment discontinuation. However, there exist no tools to identify patients that are susceptible to develop ICI-IIA. Areas covered: This non-systematic review briefly presents a sparse number of studies, that have tried to identify circulating biomarkers for early prediction of ICI-IIA. Challenges, recommendations, and possibilities related to biomarker discovery in the context of ICI-IIA are then covered. Expert opinion: Improved diagnosis adapted from rheumatological settings is needed for future studies to avoid a major pitfall of bad endpoints. Synovial tissue biopsies, omics technologies and particularly integration of multiple omics data is useful when searching for biomarkers of ICI-IIA and can also help unravel underlying biological mechanisms. Future biomarkers could ultimately aid clinical decision-making and facilitate early prophylaxis, pave the way for new treatment or even translational models to study autoimmune arthritis.

Original languageEnglish
JournalExpert Review of Precision Medicine and Drug Development
Volume7
Issue number1
Pages (from-to)162-168
ISSN2380-8993
DOIs
Publication statusPublished - 2022

Keywords

  • Biomarkers
  • ICI
  • ICI-IIA
  • immune-checkpoint inhibitors
  • inflammatory arthritis
  • irAEs
  • omics

Fingerprint

Dive into the research topics of 'Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers – Where are we now?'. Together they form a unique fingerprint.

Cite this